CLINICAL TRIAL SUMMARY

MDACC Study No:ID02-407 (clinicaltrials.gov NCT No: NCT00067002)
Title:Randomized trial of unmanipulated versus expanded cord blood
Principal Investigator:Simrit Parmar
Treatment Agent:None
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if combining cord blood
units to make the cells "take" faster in recipients will help to improve the
results of cord blood transplants.

Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation
Phase of Study:Phase II
Treatment Agents:None
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Initial phase of treatment: 30-50 days in the inpatient BMT unit.

Patients will be followed in the ATC bed unit after discharge. Readmissions may
be necessary.

Patients are expected to remain in Houston for 4 - 6 months.
Supported By:N/A
Return Visit:First 2 - 3 months post discharge, patients will be seen initially on a daily
basis.
After this period of time, patients will be evaluated on a monthly basis during
6 months, every 3 months thereafter for a year, and every 6 months thereafter.
Home Care:If needed, parenteral nutrition, antibiotics, IV fluids and antiemetics may be
given at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Simrit Parmar
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults